Hsieh Terry, Gundlach Bradley S, Ashrafzadeh Sahar, Sarraf David, Tsui Irena
Stein Eye Institute, University of California, Los Angeles, CA, USA.
David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Clin Ophthalmol. 2022 Sep 19;16:3089-3096. doi: 10.2147/OPTH.S358239. eCollection 2022.
To examine the return of patients to intravitreal injection clinic after the COVID-19 lockdown.
The electronic medical records of all patients who received intravitreal injections at a tertiary care Veterans Health Administration (VHA) clinic 14 weeks post-lockdown (5/9/20-8/13/20) in Los Angeles County were reviewed. Reference groups included injection patients during the 7-week COVID-19 lockdown (3/19/20-5/8/20) and a 7-week pre-pandemic period in 2019 (3/19/19-5/8/19). Clinic volume was compared using a one-way ANOVA. Demographic data, medical and psychiatric co-morbidities, injection diagnoses, visual acuities, and clinic volumes were compared between the 3 periods using a generalized estimating equation multivariate analysis.
The post-lockdown period group averaged 25.1 visits per week, compared with 12.3/week during lockdown and 25.4/week pre-COVID in intravitreal injection clinic. In the post-lockdown period, the VHA injection clinic returned closer to the pre-lockdown volume compared to the VHA comprehensive clinic (98.9% vs 57.4%, p < 0.001). Post-lockdown, COPD patients and organ transplant patients were less likely to receive injections compared to 2019 (OR 0.76 p = 0.008, OR 1.37 p < 0.0001, respectively). Patients with a diagnosis of cancer increased in proportion between the pre-pandemic and the post-lockdown periods (OR 1.31, p = 0.007). No differences were found, according to psychiatric co-morbidities. After lockdown, the proportion of patients receiving injections for diabetic macular edema (DME) increased (OR 1.11, p = 0.01).
Injection volume returned to pre-pandemic levels immediately after lockdown ended. However, patients with high-risk comorbidities did not return to intravitreal injection clinic post-lockdown. These results can inform medical organizations, which groups may need increased safety measures and targeted outreach to address their ophthalmic needs.
研究新冠肺炎疫情封锁结束后患者返回玻璃体内注射门诊的情况。
回顾了洛杉矶县一家三级医疗退伍军人健康管理局(VHA)门诊在封锁结束14周后(2020年5月9日至8月13日)所有接受玻璃体内注射患者的电子病历。参照组包括新冠肺炎疫情封锁7周期间(2020年3月19日至5月8日)以及2019年疫情前7周(2019年3月19日至5月8日)的注射患者。使用单因素方差分析比较门诊量。采用广义估计方程多变量分析比较三个时期的人口统计学数据、医学和精神共病情况、注射诊断、视力以及门诊量。
封锁结束后时期组平均每周就诊25.1次,而封锁期间为每周12.3次,新冠肺炎疫情前玻璃体内注射门诊为每周25.4次。在封锁结束后时期,与VHA综合门诊相比,VHA注射门诊恢复到更接近封锁前的门诊量(98.9%对57.4%,p<0.001)。封锁结束后,与2019年相比,慢性阻塞性肺疾病(COPD)患者和器官移植患者接受注射的可能性较小(优势比分别为0.76,p = 0.008;优势比为1.37,p<0.0001)。在疫情前和封锁结束后时期,诊断为癌症的患者比例有所增加(优势比为1.31,p = 0.007)。根据精神共病情况未发现差异。封锁结束后,接受糖尿病性黄斑水肿(DME)注射治疗的患者比例增加(优势比为1.11,p = 0.01)。
封锁结束后注射量立即恢复到疫情前水平。然而,患有高危共病的患者在封锁结束后未返回玻璃体内注射门诊。这些结果可为医疗机构提供参考,了解哪些群体可能需要加强安全措施和有针对性的宣传,以满足他们的眼科需求。